close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

0.5277 +0.3977 (+305.92%)
Official Closing Price Updated: 4:15 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
These stocks are making the most noise in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? ↗
The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives. 
Via Stocktwits
News headline image
Why Is Quince Therapeutics Stock Soaring Tuesday? ↗
Quince Therapeutics (NASDAQ: QNCX) engages LifeSci as financial advisor to explore strategic alternatives. Stock jumps. 
Via Benzinga
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
From Quince Therapeutics, Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Why Did QNCX Stock Plummet Over 90% Today? ↗
The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 
Via Stocktwits
Topics Bankruptcy
News headline image
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Wednesday's session: top gainers and losers ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are moving on Wednesday? ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Quince Therapeutics to Participate at Investor Events in December 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today